Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MASCC 2016 | Neuropathy risk factors and prevention

Charles Loprinzi, MD of Mayo Clinic, Rochester, MN gives an overview of neuropathy risk factors and discusses new data showing promise for neuropathy reduction. The risk factors include patient’s genetic makeup, chemotherapy drugs used, diabetes, or increased body mass index. Patient with diabetes get more trouble with neuropathy particularly when treated with paclitaxel, oxaliplatin showing mixed data. If a patient has significant neuropathy to start with, it has to be put into perspective. The treatment should be stopped and rethought, with an option to switch to another therapy. New data show that exercise may decrease neuropathy, but further research is required. In addition, data suggest that cryotherapy, also known as cold therapy, may decrease neuropathy in paclitaxel-treated patients. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Ocular Oncology (ISOO) 2016 Annual Meeting on Supportive Care in Cancer held in Adelaide, Australia.